NCT06417697View on ClinicalTrials.gov

A Phase 1b Study to Evaluate the Safety of XEN-101

PHASE1TerminatedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

September 9, 2024

Study Completion Date

September 9, 2024

Conditions

Obesity

Interventions

DRUG

XEN-101

capsule formulation

DRUG

Placebo

capsule formulation

Trial Locations (1)

3004

Nucleus Network Pty Ltd, Melbourne

Sponsors

Lead Sponsor

Xeno Biosciences

All Listed Sponsors

lead

Xeno Biosciences

INDUSTRY

NCT06417697 - A Phase 1b Study to Evaluate the Safety of XEN-101 | Biotech Hunter | Biotech Hunter